US2019216760A1PendingUtilityA1

Composition for use in treating rotavirus infection

32
Assignee: DEVENISH NUTRITION LTDPriority: Jun 30, 2016Filed: Jun 30, 2017Published: Jul 18, 2019
Est. expiryJun 30, 2036(~9.9 yrs left)· nominal 20-yr term from priority
Inventors:Violet Emma BeattieGordon Moore AllanAndrena MillarJohn Paul Mckillen
A61K 31/19A61P 31/22A61P 31/20A61P 31/14A61K 31/20A61K 31/14
32
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a composition comprising at least one carboxylic acid selected from butanoic acid, hexanoic acid, octanoic acid, decanoic acid, and dodecanoic acid for use in treating a viral infection. Also disclosed is use of a composition comprising at least one carboxylic acid selected from butanoic acid, hexanoic acid, octanoic acid, decanoic acid, and dodecanoic acid in the manufacture of a medicament for treating a viral infection; and a method for treating a viral infection in a subject.

Claims

exact text as granted — not AI-modified
1 . A method for treating a viral infection comprising administering to a subject in need thereof a composition comprising at least one carboxylic acid selected from butanoic acid, hexanoic acid, octanoic acid, decanoic acid, and dodecanoic acid. 
     
     
         2 . The method according to  claim 1 , wherein the viral infection is a Reoviridae infection. 
     
     
         3 . The method according to  claim 1 , wherein the viral infection is a rotavirus infection. 
     
     
         4 . The method according to  claim 1 , wherein the composition comprises 80% (v/v) butanoic acid and 10% (v/v) octanoic acid. 
     
     
         5 . The method according to  claim 1 , wherein the composition comprises 80% (v/v) butanoic acid, 10% (v/v) octanoic acid, and 10% (v/v) decanoic acid. 
     
     
         6 . The method according to  claim 1 , wherein the composition comprises 60% (v/v) butanoic acid, 20% (v/v) octanoic acid, and 20% (v/v) decanoic acid. 
     
     
         7 . The method according to  claim 1 , wherein the composition comprises 40% (v/v) butanoic acid, 30% (v/v) octanoic acid, and 30% (v/v) decanoic acid. 
     
     
         8 . The method according to  claim 1 , wherein the composition comprises 20% (v/v) butanoic acid, 40% (v/v) octanoic acid, and 40% (v/v) decanoic acid. 
     
     
         9 . The method according to  claim 1 , wherein the composition comprises 80% (v/v) butanoic acid and 10% (v/v) decanoic acid. 
     
     
         10 . The method according to  claim 1 , wherein the composition comprises 60% (v/v) butanoic acid and 20% (v/v) decanoic acid. 
     
     
         11 . The method according to  claim 1 , wherein the composition comprises 40% (v/v) butanoic acid and 30% (v/v) decanoic acid. 
     
     
         12 . The method according to  claim 1 , wherein the composition comprises 20% (v/v) butanoic acid and 40% (v/v) decanoic acid. 
     
     
         13 . The method according to  claim 1 , wherein the composition comprises 40% (v/v) octanoic acid and 40% (v/v) decanoic acid. 
     
     
         14 . The method according to  claim 1 , wherein the composition comprises 30% (v/v) octanoic acid and 30% (v/v) decanoic acid. 
     
     
         15 . The method according to  claim 1 , wherein the composition comprises 20% (v/v) octanoic acid and 20% (v/v) decanoic acid. 
     
     
         16 . The method according to  claim 1 , wherein the composition comprises 10% (v/v) octanoic acid and 10% (v/v) decanoic acid. 
     
     
         17 . The method according to  claim 1 , wherein the composition has a carboxylic acid concentration of 50-200 mM. 
     
     
         18 . A pharmaceutical composition for treatment of a viral infection which comprises at least one carboxylic acid selected from butanoic acid, hexanoic acid, octanoic acid, decanoic acid, and dodecanoic acid, wherein the at least one carboxylic acid comprises 80% (v/v) butanoic acid and 10% (v/v) octanoic acid, or 20-80% (v/v) butanoic acid and 10-40% (v/v) decanoic acid, or 10-40% (v/v) octanoic acid and 10-40% (v/v) decanoic acid. 
     
     
         19 . The pharmaceutical composition of  claim 18 , wherein the carboxylic acid concentration in the composition is 50-200 mM. 
     
     
         20 . A pharmaceutical composition for treatment of a viral infection which comprises at least one carboxylic acid selected from butanoic acid, hexanoic acid, octanoic acid, decanoic acid, and dodecanoic acid, wherein the at least one carboxylic acid comprises 20-80% (v/v) butanoic acid, and 10-40% (v/v) octanoic acid, and 10-40% (v/v) decanoic acid.

Join the waitlist — get patent alerts

Track US2019216760A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.